UNSPSC 51402202: Pipequaline

This classification denotes an anxiolytic with the molecular formula C22H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3S205V4I2, chemically known as quinoline, 2-phenyl-4-(2-(4-piperidinyl)ethyl)- but generally known as pipequaline, which bears US NIH Compound Identifier 71219. European Medicines Agency schedules Pipequaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09865MIG.

UNSPSC 51402202 Pipequaline, a Commodity code, covers pharmaceutical products and drug formulations procured by state and local health agencies, departments of human services, and cooperative purchasing alliances. State and local governments buy naloxone and drug deactivation systems, generic pharmaceuticals, and over-the-counter products under this code, typically in volume for community health initiatives, pharmacy benefit programs, and multi-jurisdictional distribution networks. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing organizations that aggregate demand across member agencies and participating jurisdictions.

Recent activity shows Seminole County, Florida soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually through IFB 60459723LAS (due July 26, 2023) with quarterly deliveries to the Seminole County Community Health Building; the Minnesota Multistate Cooperative Purchasing Alliance issuing RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with products supplied through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.; and the Texas Health and Human Services Commission posting RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Geographic activity concentrates in Florida, Texas, and Minnesota, with multi-state cooperative purchasing extending procurement reach across the Upper Midwest and Pacific Northwest. Contracts emphasize compliance with FDA requirements, cGMP certification, Drug Supply Chain Security Act adherence, E-Verify and drug-free workplace requirements, and comprehensive insurance coverage; vendors must integrate with authorized wholesaler networks and support electronic data interchange for pharmaceutical product ordering and fulfillment.